| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults (NCT07764237) | ModernaTX, Inc. | 2026-08-16 |
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants (NCT07737717) | ModernaTX, Inc. | 2026-07-31 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) (NCT07561294) | ModernaTX, Inc. | 2026-04-29 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (NCT07496450) | ModernaTX, Inc. | 2026-03-23 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age (NCT07478952) | ModernaTX, Inc. | 2026-03-17 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (NCT07266558) | ModernaTX, Inc. | 2025-11-26 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (NCT07116616) | ModernaTX, Inc. | 2025-09-30 |
| A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age (NCT07117487) | ModernaTX, Inc. | 2025-08-05 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations (NCT07089706) | ModernaTX, Inc. | 2025-07-21 |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (NCT06735248) | ModernaTX, Inc. | 2025-04-16 |
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (NCT06694389) | ModernaTX, Inc. | 2024-11-18 |
| A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants (NCT06655870) | ModernaTX, Inc. | 2024-10-31 |
| A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age (NCT06634797) | ModernaTX, Inc. | 2024-10-08 |
| A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (NCT06592794) | ModernaTX, Inc. | 2024-09-24 |
| A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (NCT06602024) | ModernaTX, Inc. | 2024-09-16 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (NCT06585241) | ModernaTX, Inc. | 2024-09-09 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) (NCT06508320) | ModernaTX, Inc. | 2024-07-15 |
| A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults (NCT06354998) | ModernaTX, Inc. | 2024-04-08 |
| Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants (NCT06243770) | ModernaTX, Inc. | 2024-02-16 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients (NCT06133010) | ModernaTX, Inc. | 2024-02-08 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers (NCT06143046) | ModernaTX, Inc. | 2023-11-15 |
| A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus (NCT06097299) | ModernaTX, Inc. | 2023-10-24 |
| A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age (NCT06097273) | ModernaTX, Inc. | 2023-10-19 |
| A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults (NCT06067230) | ModernaTX, Inc. | 2023-10-06 |
| A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age (NCT06060457) | ModernaTX, Inc. | 2023-09-25 |
| A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes (NCT06033261) | ModernaTX, Inc. | 2023-09-06 |
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (NCT05992935) | ModernaTX, Inc. | 2023-08-25 |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05918250) | ModernaTX, Inc. | 2023-08-15 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age (NCT05995275) | ModernaTX, Inc. | 2023-08-15 |
| A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age (NCT05975099) | ModernaTX, Inc. | 2023-07-26 |
| A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (NCT05972174) | ModernaTX, Inc. | 2023-07-10 |
| A Retrospective Study to Characterize Participants With Propionic Acidemia (NCT05769621) | ModernaTX, Inc. | 2023-06-16 |
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (NCT05868382) | ModernaTX, Inc. | 2023-05-15 |
| Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (NCT05827978) | ModernaTX, Inc. | 2023-04-17 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (NCT05827926) | ModernaTX, Inc. | 2023-04-14 |
| Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran (NCT06130345) | ModernaTX, Inc. | 2023-04-14 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants (NCT05831111) | ModernaTX, Inc. | 2023-04-05 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. (NCT05683457) | ModernaTX, Inc. | 2023-04-05 |
| A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine (NCT06113692) | ModernaTX, Inc. | 2023-03-31 |
| A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NCT05815498) | ModernaTX, Inc. | 2023-03-28 |
| A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults (NCT05827068) | ModernaTX, Inc. | 2023-03-27 |
| Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE (NCT06333704) | ModernaTX, Inc. | 2023-03-10 |
| Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy (NCT06369272) | ModernaTX, Inc. | 2023-03-01 |
| A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months (NCT05743881) | ModernaTX, Inc. | 2023-02-15 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (NCT05701800) | ModernaTX, Inc. | 2023-01-23 |
| A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure (NCT05659264) | ModernaTX, Inc. | 2022-12-05 |
| Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine (NCT05894525) | ModernaTX, Inc. | 2022-11-15 |
| Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19 (NCT05894499) | ModernaTX, Inc. | 2022-11-15 |
| Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19 (NCT05894590) | ModernaTX, Inc. | 2022-11-15 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age (NCT05575492) | ModernaTX, Inc. | 2022-11-07 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (NCT05606965) | ModernaTX, Inc. | 2022-11-02 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old (NCT05585632) | ModernaTX, Inc. | 2022-10-14 |
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (NCT05584202) | ModernaTX, Inc. | 2022-09-30 |
| Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study (NCT05572658) | ModernaTX, Inc. | 2022-09-15 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older (NCT05566639) | ModernaTX, Inc. | 2022-09-14 |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (NCT05533697) | ModernaTX, Inc. | 2022-09-01 |
| A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age (NCT05436834) | ModernaTX, Inc. | 2022-06-21 |
| Use of Wearable Digital Sensors After mRNA Vaccination in Adults (NCT05440318) | ModernaTX, Inc. | 2022-06-16 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (NCT05415462) | ModernaTX, Inc. | 2022-06-06 |
| A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) (NCT05095727) | ModernaTX, Inc. | 2022-06-01 |
| A Study of Modified mRNA Vaccines in Healthy Adults (NCT05397223) | ModernaTX, Inc. | 2022-05-24 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old (NCT05375838) | ModernaTX, Inc. | 2022-05-13 |
| A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) (NCT06189053) | ModernaTX, Inc. | 2022-04-30 |
| A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind (NCT05367908) | ModernaTX, Inc. | 2022-04-11 |
| A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (NCT05333289) | ModernaTX, Inc. | 2022-04-06 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (NCT05330975) | ModernaTX, Inc. | 2022-04-01 |
| An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 (NCT05295433) | ModernaTX, Inc. | 2022-03-08 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 (NCT05249829) | ModernaTX, Inc. | 2022-02-16 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults (NCT05164094) | ModernaTX, Inc. | 2021-12-28 |
| Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination (NCT04941144) | ModernaTX, Inc. | 2021-12-22 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters (NCT05137236) | ModernaTX, Inc. | 2021-12-06 |
| A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age (NCT05127434) | ModernaTX, Inc. | 2021-11-17 |
| A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study (NCT05130437) | ModernaTX, Inc. | 2021-11-09 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 (NCT05105048) | ModernaTX, Inc. | 2021-11-08 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age (NCT05085366) | ModernaTX, Inc. | 2021-10-26 |
| A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults (NCT05366322) | ModernaTX, Inc. | 2021-09-10 |
| Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study (NCT04958304) | ModernaTX, Inc. | 2021-09-01 |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia (NCT04899310) | ModernaTX, Inc. | 2021-08-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults (NCT04916431) | ModernaTX, Inc. | 2021-07-28 |
| Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States (NCT04958954) | ModernaTX, Inc. | 2021-07-07 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults (NCT04956575) | ModernaTX, Inc. | 2021-07-06 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine (NCT04975893) | ModernaTX, Inc. | 2021-06-18 |
| A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas (NCT04917861) | ModernaTX, Inc. | 2021-06-07 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (NCT04927065) | ModernaTX, Inc. | 2021-05-28 |
| A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants (NCT04860297) | ModernaTX, Inc. | 2021-04-16 |
| Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia (NCT04159103) | ModernaTX, Inc. | 2021-04-15 |
| A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age (NCT04796896) | ModernaTX, Inc. | 2021-03-15 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 (NCT04813796) | ModernaTX, Inc. | 2021-03-11 |
| A Study of the Effectiveness of Moderna COVID-19 Vaccine (NCT05933304) | ModernaTX, Inc. | 2020-12-18 |
| A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (NCT04649151) | ModernaTX, Inc. | 2020-12-09 |
| A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive (NCT04528719) | ModernaTX, Inc. | 2020-09-30 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 (NCT04470427) | ModernaTX, Inc. | 2020-07-27 |
| Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older (NCT04405076) | ModernaTX, Inc. | 2020-05-29 |
| Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults (NCT04232280) | ModernaTX, Inc. | 2020-01-09 |
| Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure (NCT04144348) | ModernaTX, Inc. | 2019-11-04 |
| Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults (NCT04064905) | ModernaTX, Inc. | 2019-07-30 |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (NCT03897881) | ModernaTX, Inc. | 2019-07-18 |
| Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia (NCT03810690) | ModernaTX, Inc. | 2019-05-28 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults (NCT03829384) | ModernaTX, Inc. | 2019-01-22 |
| Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies (NCT03739931) | ModernaTX, Inc. | 2018-11-27 |